98%
921
2 minutes
20
Improvements in cancer care require a new degree of collaboration beyond the purely medical sphere, extending deeply into the world of other stakeholders-preeminently patients but also the other stakeholders in the hardware and software of care. Cancer remains a global health challenge, necessitating collaborative efforts to understand, prevent, and treat this complex disease. To achieve this goal, a comprehensive analysis was conducted, aligning the prioritization of cancer research measures in 13 European countries with 13 key recommendations for conquering cancer in the region. The study utilized a survey involving both patients and citizens, alongside data from IQVIA, a global healthcare data provider, to assess the availability and access to single-biomarker tests in multiple European countries. The results revealed a focused approach toward understanding, preventing, and treating cancer, with each country emphasizing specific research measures tailored to its strengths and healthcare objectives. This analysis highlights the intricate relationship between research priorities, access to biomarker tests, and financial support. Timely access to tests and increased availability positively influence research areas such as cancer prevention, early detection, ageing, and data utilization. The alignment of these country-specific measures with 13 recommendations for conquering cancer in Europe underscores the importance of tailored strategies for understanding, preventing, and treating cancer.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10815829 | PMC |
http://dx.doi.org/10.3390/healthcare12020259 | DOI Listing |
Cureus
July 2025
Infectious Disease, Zydus Lifesciences, Ahmedabad, IND.
Influenza remains a major health concern, especially for patients with chronic respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Despite clear evidence of its benefits, annual influenza vaccination rates in India remain critically low, particularly among high-risk populations and healthcare professionals (HCPs). Key barriers include misinformation, lack of provider recommendation, and absence of structured vaccination programs.
View Article and Find Full Text PDFAnn Surg Oncol
June 2025
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Background: Appendiceal tumors comprise a heterogeneous group of tumors that may be localized or disseminate throughout the peritoneum. Limited high quality clinical data exist and many practices have been extrapolated from colorectal cancer without validation in appendiceal cohorts. There are many controversies regarding the treatment of appendiceal tumors, and practices vary widely between centers and care settings.
View Article and Find Full Text PDFCancer
July 2025
Division of Surgical Oncology, Department of Surgery, University of California San Diego, San Diego, California, USA.
The peritoneum is a common site of metastases from colorectal cancer (CRC), yet controversy exists regarding optimal treatment strategies. These guidelines describe the results of a national consensus addressing the management of CRC with peritoneal metastases (CRC-PM). An update of the 2018 Chicago consensus guidelines was conducted with a modified Delphi technique.
View Article and Find Full Text PDFBreast Cancer Res
June 2025
Division of Hematology/Oncology, University of Pittsburgh School of Medicine, and UPMC Hillman Cancer Center, 300 Halket Street, Room 3524, Pittsburgh, PA, 15213, USA.
Purpose: Based on improved survival, the 2017 ASCO and Cancer Care Ontario clinical guidelines (ACGD) recommended consideration of adjuvant bisphosphonates for postmenopausal women with early-stage breast cancer (EBC). However, small survey-based studies suggest inconsistent prescribing. This study evaluated receipt of adjuvant bone modifying agents (BMAs) in the United States before and after publication of the 2017 ACGD.
View Article and Find Full Text PDFJ Manag Care Spec Pharm
June 2025
McKesson and The US Oncology Network, Boise, ID.
Precision medicine in oncology using actionable molecular biomarkers to guide treatment selection has been associated with favorable outcomes; however, many potentially eligible patients do not receive it. This Academy of Managed Care Pharmacy Market Insights program sought to characterize unmet needs in biomarker testing among managed care stakeholders, to develop best practice and consensus recommendations to support addressing these needs, and to gain insights on potential quality measures related to biomarker testing. The program used a modified Delphi process and included in-depth interviews with expert panelists, a national survey of managed care professionals, and a consensus survey of experts.
View Article and Find Full Text PDF